Shares of GenVec Inc. (NASDAQ:GNVC) have been assigned an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.
Analysts have set a 1 year consensus price objective of $2.15 for the company and are predicting that the company will post ($0.08) EPS for the current quarter, according to Zacks. Zacks has also given GenVec an industry rank of 107 out of 265 based on the ratings given to its competitors.
GNVC has been the subject of several research reports. Zacks Investment Research raised shares of GenVec from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a research report on Thursday, July 28th. Roth Capital reissued a “buy” rating and issued a $2.00 price objective (down from $8.00) on shares of GenVec in a research report on Tuesday, July 26th. Finally, Rodman & Renshaw reissued a “buy” rating and issued a $2.30 price objective on shares of GenVec in a research report on Monday, June 20th.
A hedge fund recently bought a new stake in GenVec stock. Sabby Management LLC purchased a new stake in shares of GenVec Inc. (NASDAQ:GNVC) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,625,435 shares of the biopharmaceutical company’s stock, valued at approximately $931,000. Sabby Management LLC owned approximately 7.15% of GenVec as of its most recent filing with the SEC. Hedge funds and other institutional investors own 26.79% of the company’s stock.
Shares of GenVec (NASDAQ:GNVC) traded up 3.45% during trading on Friday, hitting $0.42. 23,296 shares of the stock traded hands. GenVec has a 12 month low of $0.35 and a 12 month high of $3.69. The stock’s market cap is $9.55 million. The firm’s 50-day moving average price is $0.54 and its 200-day moving average price is $0.64.
GenVec (NASDAQ:GNVC) last released its quarterly earnings results on Friday, August 5th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.04. GenVec had a negative net margin of 927.05% and a negative return on equity of 83.14%. Analysts anticipate that GenVec will post ($0.29) EPS for the current year.
GenVec, Inc (GenVec) is a clinical-stage biopharmaceutical company, engaged in the development of therapeutics and vaccines. The Company designs, tests and manufactures adenoviral-based product candidates. The Company’s development programs address therapeutic areas, such as hearing loss and balance disorders, as well as vaccines against infectious diseases, including respiratory syncytial virus (RSV), herpes simplex virus (HSV), Enterovirus D68 (EV-D68) and malaria.